

TENNESSEE GENERAL ASSEMBLY
FISCAL REVIEW COMMITTEE



FISCAL NOTE

HB 992

February 10, 2021

SUMMARY OF BILL: Requires the Division of TennCare (Division) to annually review all medications and forms of treatment for sickle cell disease, and services for enrollees with a diagnosis of sickle cell disease that are eligible for coverage. Requires the Division submit the results of this study, along with any recommendations, to the Chief Clerks of the Senate and the House of Representatives and the legislative librarian by January 15, 2022 and every January 15 thereafter.

ESTIMATED FISCAL IMPACT:

NOT SIGNIFICANT

Assumption:

- The Division will complete the study and prepare the required report utilizing existing resources without an increased appropriation or reduced reversion.

IMPACT TO COMMERCE:

NOT SIGNIFICANT

Assumption:

- No impact on commerce or jobs in Tennessee.

CERTIFICATION:

The information contained herein is true and correct to the best of my knowledge.

A handwritten signature in black ink that reads "Bojan Savic".

Bojan Savic, Interim Executive Director

/vh